Skip to main content
Log in

Solifenacin Demonstrates High Absolute Bioavailability in Healthy Men

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Objective

Solifenacin succinate (YM905; Vesicare®) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10mg, which is twice the suggested starting dose.

Study design

Single-centre, open-label, randomised, two-period, crossover, single-dose study.

Methods

Solifenacin was administered orally as a 10mg dose and intravenously as a 5mg dose. Oral and intravenous (IV) doses were divided by a washout period of ≥14 days.

Study participants

The study group consisted of 12 healthy young men, aged 20–45 years, nine of whom completed the study.

Results

The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence.

Conclusions

Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78

    Article  PubMed  Google Scholar 

  2. Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135–40

    Article  PubMed  CAS  Google Scholar 

  3. Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001; 20: 406–8

    Google Scholar 

  4. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6: S565–73

    PubMed  CAS  Google Scholar 

  5. Abrams P, Kelleher CJ, Kerr L, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 Suppl. 11: S580–90

    PubMed  CAS  Google Scholar 

  6. Cardozo L, Kuzmin I, Lisec ML, et al. YM905 in symptomatic overactive bladder: results of a Phase 3A randomised, placebo-controlled trial [abstract]. J Urol 2003; 169 Suppl. 4: 350

    Google Scholar 

  7. Chapple CR, Araño P, Bosch JLHR, et al. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase II, dose-finding study [abstract]. Neurourol Urodyn 2002; 21: 381–2

    Google Scholar 

  8. Smith N, Grimes I, Ridge S, et al. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  9. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97–103

    Article  PubMed  CAS  Google Scholar 

  10. Smulders RA, Krauwinkel W, Abila B, et al. 10- and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: pharmacokinetics, pharmacodynamics, and safety in healthy, elderly men and women [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  11. Smith N, van Zijtfeld J, Swart PJ. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  12. Smulders RA, Tan HT, Krauwinkel W, et al. A placebo-controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  13. Smulders RA, van Alphen WW, Visser JN, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  14. Uchida T, Smulders RA, Abila B, et al. Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002

    Google Scholar 

  15. Douchamps J, Derenne F, Stockis A, et al. The pharmaco-kinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515–20

    Article  PubMed  CAS  Google Scholar 

  16. Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287–95

    PubMed  CAS  Google Scholar 

  17. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227–35

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan. The authors have no conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mirjam E. Kuipers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuipers, M.E., Krauwinkel, W.J.J., Mulder, H. et al. Solifenacin Demonstrates High Absolute Bioavailability in Healthy Men. Drugs R D 5, 73–81 (2004). https://doi.org/10.2165/00126839-200405020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200405020-00002

Keywords

Navigation